Skip to content
Open access · CC-BY via OpenAlex

Unraveling the Synergistic Inhibition of Human Maltase–Glucoamylase by Baicalein and Acarbose: Integrated Pharmacodynamics and Computational Insights

Xiaoshi He, Xia Li, Danyang Zhang, Hui Jiang, Yuesheng Dong

Pharmaceuticals · 2026

Abstract

Background: Combining natural products with conventional antidiabetic agents to inhibit α-glucosidase activity is an effective strategy for preventing postprandial hyperglycemia. Baicalein, a natural flavonoid with well-documented low toxicity, showed potential synergistic effect with acarbose in diabetic models; however, the synergistic performance and mechanisms of the two agents targeting human maltase–glucoamylase (MGAM) remain unclear. Methods: Recombinant human MGAM-C and MGAM-N were expressed in Pichia pastoris for in vitro inhibition assays. Maltose-loaded mice were used to assess the in vivo hypoglycemic activity and intestinal maltase inhibition. Inhibitor–enzyme interactions were investigated by fluorescence spectroscopy, circular dichroism (CD), multiple molecular docking, and molecular dynamics (MD) simulations. Results: Baicalein potently inhibited MGAM-C and MGAM-N with IC50 values of 20.41 ± 4.80 μM and 14.04 ± 0.94 μM, respectively, and demonstrated a synergistic effect when combined with acarbose. In vivo, co-administration significantly reduced blood glucose levels and suppressed small intestinal maltase activity in maltose-loaded mice. Mechanistic studies revealed that baicalein functions as a non-competitive inhibitor by binding to the allosteric site of MGAM-C via stable hydrogen bonds with residues Ile1716 and Trp1749. This interaction induces conformational changes in the enzyme’s secondary structure and optimizes the hydrophobic microenvironment of the active site, thereby enhancing the binding affinity and hydrogen bond stability of acarbose. These molecular events collectively contribute to the synergistic inhibition of MGAM-C hydrolytic activity. Conclusions: This research revealed the synergistic inhibitory effect of baicalein and acarbose on MGAM and the underlying mechanisms, thereby providing a theoretical basis for developing pharmaceutical formulations to enhance acarbose efficacy.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.3390/ph19081215
Canonical
link ↗
Fetched
2026-11-12 MST

Cite this

APA
He, X., Li, X., Zhang, D., Jiang, H., &amp; Dong, Y. (2026). Unraveling the Synergistic Inhibition of Human Maltase–Glucoamylase by Baicalein and Acarbose: Integrated Pharmacodynamics and Computational Insights. <em>Pharmaceuticals</em>. https://doi.org/10.3390/ph19081215
Vancouver
He X, Li X, Zhang D, Jiang H, Dong Y. Unraveling the Synergistic Inhibition of Human Maltase–Glucoamylase by Baicalein and Acarbose: Integrated Pharmacodynamics and Computational Insights. Pharmaceuticals. 2026. doi:10.3390/ph19081215.
BibTeX
@article{xiaoshi2026Unrave, title = {Unraveling the Synergistic Inhibition of Human Maltase–Glucoamylase by Baicalein and Acarbose: Integrated Pharmacodynamics and Computational Insights}, author = {Xiaoshi He and Xia Li and Danyang Zhang and Hui Jiang and Yuesheng Dong}, journal = {Pharmaceuticals}, year = {2026}, doi = {10.3390/ph19081215}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings